{"id":"W3203425821","doi":"10.51731/cjht.2021.168","title":"Nivolumab (Opdivo) in combination with Ipilimumab (Yervoy)","year":2021,"lang":"en","type":"article","venue":"Canadian Journal of Health Technologies","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"","keywords":"Ipilimumab; Nivolumab; Reimbursement; Medicine; Drug; Internal medicine; Oncology; Pharmacology; Immunotherapy; Cancer","routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007261978,0.0002561339,0.000300437,0.0005914546,0.0001571825,0.0007323805,0.000345041,0.0003405553,0.005435604],"category_scores_gemma":[0.0005185817,0.00008121703,0.0005042718,0.0004256518,0.0002168089,0.0003878438,0.0002501083,0.00035574,0.00126506],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001729091,"about_ca_system_score_gemma":0.00199793,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.01427791,"about_ca_topic_score_gemma":0.05773721,"domain_scores_codex":[0.9996998,0.00009251363,0.000032254,0.00003919834,0.00009347517,0.00004280948],"domain_scores_gemma":[0.9998119,0.00003793743,0.0000583294,0.000007566414,0.00006458798,0.00001968412],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0009283766,0.00009144268,0.002743716,0.004438863,0.0003632851,0.0002028717,0.0000371694,0.000389759,0.01341316,0.003027864,0.04380918,0.9305543],"study_design_scores_gemma":[0.0005146129,0.0019405,0.01666101,0.003678225,0.0006818394,0.001413485,0.000107611,0.0005103384,0.01980708,0.0007298154,0.9539231,0.00003236694],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.03877813,0.8333762,0.00240338,0.005496336,0.001230065,0.0003317551,0.001739762,0.0002351056,0.1164092],"genre_scores_gemma":[0.3905527,0.5016907,0.01104853,0.007693074,0.0006143988,0.0003176871,0.003327677,0.00005699796,0.08469816],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.01427791,"threshold_uncertainty_score":0.02838957,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02037484201940579,"score_gpt":0.2716369777010043,"score_spread":0.2512621356815985,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}